Quantisnow Logo
Dashboard
Subscribe to $CFMS

Conformis Inc.

$CFMS
Industrial Specialties
Health Care

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

IPO Year: 2015

Exchange: NASDAQ

Website: conformis.com

Recent Analyst Ratings for Conformis Inc.

DatePrice TargetRatingAnalyst
11/4/2021$2.50 → $2.00Outperform
Oppenheimer
9/22/2021$3.00 → $2.50Outperform
Oppenheimer
See more ratings

Conformis Inc. Press Releases

Fastest customizable press release news feed in the world

See more

  • restor3d Completes Acquisition of Conformis

    DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis' stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis' common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023. "We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body," said J. Kurt Jacobus, CEO o

    $CFMS
    Industrial Specialties
    Health Care

  • Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

    BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), have each recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS and Glass Lewis share its be

    $CFMS
    Industrial Specialties
    Health Care

  • Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3d

    BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that Conformis stockholders vote "FOR" the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best inte

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Reports Second Quarter 2023 Financial Results

    BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue of $1.0 million, an increase of 30% year-over-year.Cash and cash equivalents of $26.2 million as of June 30, 2023.Announced merger agreement to be acquired by

    $CFMS
    Industrial Specialties
    Health Care

  • Lifshitz Law PLLC Announces Investigations of KLR, CFMS, TALS, and SGTX

    NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) -- Kaleyra, Inc. (NYSE:KLR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash. If you are a KLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. Conformis Inc. (NASDAQ:CFMS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CFMS to Restor3d, Inc. for $2.27 per share in cash.

    $CFMS
    $KLR
    $SGTX
    $TALS
    Industrial Specialties
    Health Care
    EDP Services
    Technology

  • Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash

    DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ:CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on June 22, 2023. "This combination will create a leading personalized 3D-printed medical device company. Together, we share a common belief in the power of personalization. By leveraging the strengths in our respective portfolios around art

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Reports First Quarter 2023 Financial Results

    BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

    BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement Procedures

    BILLERICA, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, recently launched a patient education and awareness campaign in selected U.S. markets to strengthen the importance of patient choice by highlighting the differences between traditional "off-the-shelf" products and truly personalized knee systems that offer clinically proven benefits to patients. The campaign is currently airing in the Boston, MA and Minneapolis-St. Paul, MN metro areas in an effort to educate future patients about their options when it comes to total knee replacement surgery. Independent surveys

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

    BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

    $CFMS
    Industrial Specialties
    Health Care

Conformis Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

Conformis Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Conformis Inc. SEC Filings

See more

Conformis Inc. Leadership Updates

Live Leadership Updates

See more

  • Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

    BILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Operating Officer. Mike brings to this role 30 years of experience in manufacturing and operations with a strong focus in precision metal products, medical devices, continuous improvement, and strategic business planning," said Mark Augusti, President and Chief Executive officer. "I look forward to the contributions he will make as a member of the Conformis team." Michael Fillion Prior to joining Conformis, Michael served as the Executive Vice Pr

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

    BILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Pedulla as Chief Legal Officer and Corporate Secretary. Her strong public company experience and leadership capabilities will help support our growth strategy and further strengthens our executive team," said Mark Augusti, President and Chief Executive Officer. "I look forward to the contributions she will make as a member of the Conformis team." Denise Pedulla Prior to joining Conformis, Denise served as the General Counsel and Corporate Secreta

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported

    BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.P. of U.S. Marketing. As we continue to advance our growth strategy, we are confident that James' extensive background in new product introductions and multi-channel marketing will help to strengthen Conformis brand recognition and position us to capitalize on anticipated growth in the ambulatory surgery center space," said Mark Augusti, President and Chief Executive Officer.  "I look forward to the contributions James will make as a member of Confo

    $CFMS
    Industrial Specialties
    Health Care

Conformis Inc. Financials

Live finance-specific insights

See more

  • Conformis Reports First Quarter 2023 Financial Results

    BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip system revenue of $0.8 million, an increase of 3% year-over-year.Cash and cash equivalents of $37.8 million as of March 31, 2023.   Three months ended March 31,

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

    BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in access. Date and Time

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results

    BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% on a constant currency basis.Hip system revenue of $0.6 million, a decrease of 15% year-over-year.Cash and cash equivalents of $48.7 million as of December 31, 2022.First procedur

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022

    BILLERICA, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, provided today a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022. Executive Commentary – Mark Augusti, President and CEO "Today we are announcing the launch of our new advertising campaign highlighting our Image-to-Implant Platinum Services program. This campaign focuses on highlighting the benefits of a fully personalized knee to patients and will launch initially in a select number of targeted markets. We are also providing an update of our

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022

    BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial-in

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Reports Third Quarter 2022 Financial Results

    BILLERICA, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Summary Total revenue of $13.8 million, a decrease of 3% year-over-year on a reported basis and 2% on a constant currency basis.Product revenue of $13.6 million, a decrease of 3% year-over-year on a reported basis and 2% on a constant currency basis.Conformis hip system revenue of $0.6 million, a decrease of 19% year-over-year.Cash and cash equivalents of $59.6 million as of September 30, 2022. Executive Comm

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022

    BILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Wednesday, November 2, 2022. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call later that day at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephone, please use the information below for dial

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Reports Second Quarter 2022 Financial Results

    BILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Summary Total revenue of $15.3 million. Total revenue in the second quarter of 2021 included significant non-recurring royalty revenue.Product revenue of $15.1 million, remained flat year-over-year on a reported basis and increased 1% on a constant currency basis.Conformis hip system revenue of $0.7 million, a decrease of 18% year-over-year.Cash and cash equivalents of $72.6 million as of June 30, 2022. Ex

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

    BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the market closes on Monday, August 8, 2022. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call the next day before the market opens on Tuesday, August 9, 2022, at 8:30 a.m. Eastern Time to discuss the financial results and to provide a business update. Earnings Call and Webcast Details: The webcast of the earnings call will be live at: Link Directly to Webcast To attend by telephon

    $CFMS
    Industrial Specialties
    Health Care

  • Conformis Reports First Quarter 2022 Financial Results

    BILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 Summary Total revenue of $15.6 million, an increase of 12% year-over-year on a reported basis and 13% on a constant currency basis.Product revenue of $14.9 million, an increase of 9% year-over-year on a reported and constant currency basis.Conformis hip system revenue up 18% year-over-year to $0.8 million.Cash and cash equivalents of $82.7 million as of March 31, 2022.Recently completed the 250th Imprint procedure

    $CFMS
    Industrial Specialties
    Health Care

Conformis Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more